Expert Comparison: Wegovy vs Mounjaro Mechanisms & UK Availability
Is Wegovy Better Than Mounjaro for Online Purchase in the UK?
When evaluating whether Wegovy is better than Mounjaro for online purchase, the answer depends on individual factors rather than one treatment being universally superior. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics natural fullness hormones, while Mounjaro contains tirzepatide, which targets both GLP-1 and GIP receptors as a dual agonist. This fundamental difference in mechanism means they may work differently for different patients, making personalised prescriber guidance essential.
At EverydayMeds, both treatments are available through the same streamlined online process, but Wegovy offers certain practical advantages for UK patients. The convenience factor often influences whether Wegovy is better than Mounjaro for your specific circumstances, particularly regarding storage flexibility and established clinical evidence. Our GPhC-registered pharmacy (#9012878) ensures you receive genuine medications regardless of which option your prescriber recommends after clinical assessment.
Wegovy vs Mounjaro Pricing: Complete UK Cost Breakdown
Understanding the cost difference is crucial when determining if Wegovy is better than Mounjaro for your budget. Wegovy pricing at EverydayMeds starts with the 0.25mg starter dose at £79.99, progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to the maintenance 2.4mg dose at £209.99. New customers benefit from discount code FIRST40, while returning customers use DOSE25, both applied at checkout to reach these final prices.
Our bundle options provide supply security without the need for frequent reordering. The Intro Duo (0.25mg & 0.5mg) costs £169.99, while the Progress Trio (0.5mg, 1mg & 1.7mg) is available for £369.99. The Ultimate Stability Trio provides three months of maintenance 2.4mg supply for £649.99. When comparing whether Wegovy is better than Mounjaro, consider that Wegovy's established NHS pathway and NICE approval (TA875) may influence future insurance coverage and accessibility.
Clinical Evidence: Is Wegovy Better Than Mounjaro Based on Research?
Direct comparison of clinical trial results cannot definitively answer whether Wegovy is better than Mounjaro, as the studies used different populations, endpoints, and methodologies. In the STEP clinical trials, patients taking Wegovy alongside diet and exercise achieved an average of approximately clinically studied weight loss at 68 weeks (Wilding et al., NEJM, 2021). The SELECT trial also demonstrated a 20% reduction in major cardiovascular events, adding important safety data to Wegovy's profile.
Mounjaro's SURMOUNT trials showed different results with its dual-agonist mechanism, but comparing these percentages directly would be misleading due to varying trial designs. The question of whether Wegovy is better than Mounjaro ultimately depends on individual response, tolerability, and medical history rather than raw efficacy numbers. Both are prescription-only medicines that must be used alongside a reduced-calorie diet and increased physical activity for optimal results.
How Wegovy Works: Understanding the GLP-1 Mechanism
Wegovy functions as a GLP-1 receptor agonist, mimicking the action of glucagon-like peptide-1, a natural hormone that regulates appetite and satiety. When administered as a once-weekly injection using the FlexTouch pen, semaglutide binds to GLP-1 receptors in the brain's appetite centres, promoting feelings of fullness and reducing food cravings. This mechanism helps patients feel satisfied with smaller portions and may reduce the frequency of eating episodes between meals. The medication works best when combined with lifestyle modifications, as it enhances the body's natural signals for portion control rather than replacing the need for healthy eating habits. Understanding this mechanism is important when considering whether Wegovy is better than Mounjaro, as the single-target approach may suit patients who respond well to GLP-1 stimulation alone.
Ordering Process: Wegovy vs Mounjaro Online Assessment
The ordering process is identical whether you're considering if Wegovy is better than Mounjaro, starting with our 3-minute online clinical assessment covering medical history, current medications, and weight management goals. Our registered prescribers review applications within 3 working days (or 24 hours with express service) to determine suitability for either treatment. Once approved, genuine Wegovy or Mounjaro is dispatched via next-day cold-chain delivery to maintain temperature integrity throughout transit. The assessment considers factors like previous GLP-1 experience, diabetic status, and individual risk factors to recommend the most appropriate option. Our clinical team at GPhC-registered pharmacy #9012878 ensures both treatments meet the same rigorous standards for authenticity and proper handling before dispatch.
Storage & Practical Considerations: Wegovy vs Mounjaro Convenience
Storage requirements often influence whether Wegovy is better than Mounjaro for practical daily use, with Wegovy offering superior flexibility for travel and lifestyle needs. Wegovy pens maintain stability for up to 6 weeks at room temperature (below 30°C) once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. Both require refrigeration at 2-8°C before first use, but Wegovy's extended room temperature tolerance makes it more suitable for extended travel, shift work, or situations where refrigeration access is limited. The FlexTouch pen system is identical for both medications, featuring the same injection technique and dose escalation schedule from starter doses through to maintenance. This storage advantage often tips the balance when patients are deciding whether Wegovy is better than Mounjaro for their specific lifestyle requirements.
UK Regulatory Status: Why Wegovy vs Mounjaro Approval Matters
The regulatory landscape influences whether Wegovy is better than Mounjaro for UK patients, with Wegovy benefiting from established NICE guidance (TA875) and longer market presence. Wegovy received MHRA approval with comprehensive weight management indication for adults with BMI ≥30 or BMI ≥27 with comorbidities, plus approval for adolescents ≥12 years. The recent approval of 7.2mg higher-dose Wegovy on 6 January 2026 demonstrates ongoing regulatory confidence, though this dose isn't yet available at EverydayMeds.
Both treatments carry the Black Triangle ▼ symbol indicating additional monitoring, but Wegovy's longer clinical experience provides more real-world safety data for prescriber confidence. When considering whether Wegovy is better than Mounjaro, the established NHS pathways and potential future insurance coverage may favour Wegovy for long-term accessibility. Our prescribers stay current with all regulatory updates to ensure patients receive the most appropriate treatment based on current licensing and safety data.
Making Your Decision: Expert Wegovy vs Mounjaro Consultation
Rather than asking whether Wegovy is better than Mounjaro in absolute terms, focus on which treatment aligns with your individual circumstances, medical history, and lifestyle needs. Both are available from EverydayMeds with identical consultation standards, delivery processes, and clinical support. Your prescriber will consider factors including previous weight loss attempts, diabetic status, cardiovascular risk, and medication tolerance when recommending between these options. The decision between Wegovy and Mounjaro should be made collaboratively with healthcare professionals who understand your complete medical picture. Start your assessment today to receive personalised guidance on whether Wegovy is better than Mounjaro for your specific weight management journey, with genuine medications available from £79.99 using discount codes FIRST40 (new customers) or DOSE25 (returning customers) applied at checkout.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
